| Species |
Mouse |
| Protein Construction |
CXCL5 (Ala41-Gln132)
Accession # P50228 |
|
| Purity |
> 97% as analyzed by SDS-PAGE
> 97% as analyzed by HPLC |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human peripheral blood neutrophils is in a concentration of 10.0-100.0 ng/ml. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
9.8 kDa |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 150 mM NaCl. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The mouse homolog of ENA-78 is called LIX. ENA-78/LIX is a CXC chemokine that signals through the CXCR2 receptor. It is expressed in monocytes, platelets, endothelial cells, and mast cells. ENA-78/LIX is a chemoattractant for neutrophils. The three naturally occurring variants of human ENA-78; ENA 5-78, ENA 9-78 and ENA 10-78, contain 74, 70, and 69 amino acid residues, respectively, and possess the same biological activity. ENA-78/LIX contains the four conserved cysteine residues present in CXC chemokines, and also contains the 'ELR' motif common to CXC chemokine that bind to the CXCR1 and CXCR2 receptors. |
| Synonyms |
C-X-C motif chemokine 5; Small-inducible cytokine B5; Cytokine LIX; Scyb5; GCP-2; Scyb6; ENA-78; AMCF-II; Epithelial Neutrophil Activating Peptide-78 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
